Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Hutchmed Limited is currently managing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This single action is being reviewed within 1 distinct art unit, reflecting a very specific focus for the company's current intellectual property docket. The involvement of only 1 distinct examiner means that the company's immediate prosecution results are determined by a single individual's assessment. This concentration in the Biotechnology & Pharmaceuticals sector suggests a targeted approach to patenting.
The busiest examiner, HUYNH, PHUONG N, is responsible for 1 busiest_examiner_pending action, which constitutes the entire active portfolio. Practitioners should focus on the specific examiner's past decisions and technical expertise, as HUYNH, PHUONG N is the only official currently reviewing the company's work. The lack of activity across other 1 distinct art units simplifies the administrative burden but increases the importance of this single 1 pending office action. Successfully navigating the requirements of HUYNH, PHUONG N is essential for the company's current biotech strategy.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HUYNH, PHUONG N | 1 | 65.8% | +53.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19374186 | NOVEL PI3K AND/OR PIKK INHIBITORS, ANTIBODY-DRUG CONJUGATES COMPRISING THE SAME AND USES THEREOF | HUYNH, PHUONG N | — |
| Art Unit | Apps |
|---|---|
| 1641 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19374186 | NOVEL PI3K AND/OR PIKK INHIBITORS, ANTIBODY-DRUG CONJUGATES COMPRISING THE SAME AND USES THEREOF | HUYNH, PHUONG N | 1641 | §112 | Non-Final OA | — | Pending | Oct 30, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialHutchmed Limited has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Phuong N Huynh has the most, with 1 of Hutchmed Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
